Calcium folinate pentahydrate
Pancreatic Adenosquamous Carcinoma
Revolution Medicines, Inc.Small moleculePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Pancreatic Adenosquamous Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM Revolution Medicines, Inc. | Phase 3 | BB |
Irinotecan Revolution Medicines, Inc. | Phase 3 | BB |
Daraxonrasib Revolution Medicines, Inc. | Phase 3 | B |
Eloxatin Revolution Medicines, Inc. | Phase 3 | B |
Zoldonrasib Revolution Medicines, Inc. | Phase 3 | B |
CIS-DIAMMINEDICHLOROPLATINUM II Alliance for Clinical Trials in Oncology | Phase 2/3 | B |
Olaparib National Cancer Institute (NCI) | Phase 2 | CCC |
Same molecule, other indications
Calcium folinate pentahydrate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →